Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome von Child, F., Ortiz-Romero, P.L., Alvarez, R., Bagot, M., Stadler, R., Weichenthal, M., Alves, R., Quaglino, P., Beylot-Barry, M., Cowan, R., Geskin, L.J., Pérez-Ferriols, A., Hellemans, P., Elsayed, Y., Phelps, C., Forslund, A., Kamida, M., Zinzani, P.L.

Volltext

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma von Usmani, Saad Z., Nahi, Hareth, Mateos, Maria-Victoria, van de Donk, Niels W.C.J., Chari, Ajai, Kaufman, Jonathan L., Moreau, Philippe, Oriol, Albert, Plesner, Torben, Benboubker, Lotfi, Hellemans, Peter, Masterson, Tara, Clemens, Pamela L., Luo, Man, Liu, Kevin, San-Miguel, Jesus

Volltext

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours von Konings, I R H M, de Jonge, M J A, Burger, H, van der Gaast, A, van Beijsterveldt, L E C, Winkler, H, Verweij, J, Yuan, Z, Hellemans, P, Eskens, F A L M

Volltext

Genetic markers in clinically well defined patients with ulcerative colitis (UC) von BOUMA, G., CRUSIUS, J. B. A., GARCÍA‐GONZÁLEZ, M. A., MEIJER, B. U. G. A., HELLEMANS, H. P. R., HAKVOORT, R. J., Th. SCHREUDER, G. M., KOSTENSE, P. J., MEUWISSEN, S. G. M., PEÑA, A. S.

Volltext

Prognostic value of bcl-2 expression in invasive breast cancer von HELLEMNAS, P, VAN DAM, P. A, WEYLER, J, VAN OOSTEROM, A. T, BUYTAERT, P, VAN MARCK, E

Volltext

1234 POSTER A First in Man Phase 1 Study of JNJ-26481585, a Novel Oral Histone Deacetylase Inhibitor (HDACi) in Advanced Cancer Patients -Evidence of Target Modulation, Antitumour... von Omlin, A, Venugopal, B, Kristeleit, R, Shah, K, Fourneau, N, Hellemans, P, de Bono, J, Plummer, R, Banerji, U, Evans, J

Volltext

Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study von Nahi, Hareth, Usmani, Saad Z., Mateos, Maria-Victoria, van de Donk, Niels W.C.J., Moreau, Philippe, Oriol, Albert, Plesner, Torben, Bandyopadhyay, Nibedita, Hellemans, Peter, Tromp, Brenda, Nnane, Ivo, Zemlickis, Donna, Farnsworth, Andrew, Chari, Ajai

Volltext

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase... von Nahi, H, Usmani, SZ, Mateos, MV, van de Donk, NWCJ, Oriol, A, Plesner, T, Bandyopadhyay, N, Hellemans, P, Tromp, B, Nnane, I, Zemlickis, D, Chari, A, Moreau, P

Volltext

Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, p... von Nahi, Hareth, Usmani, Saad Zafar, Mateos, Maria-Victoria, van de Donk, Niels W.C.J., Moreau, Philippe, Oriol, Albert, Plesner, Torben, Yang, Shiyi, Hellemans, Peter, Tromp, Brenda J., Luo, Man (Melody), Zemlickis, Donna, Farnsworth, Andrew, Chari, Ajai

Volltext

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO) von San-Miguel, Jesus, Usmani, Saad Z, Mateos, Maria-Victoria, van de Donk, Niels W C J, Kaufman, Jonathan L, Moreau, Philippe, Oriol, Albert, Plesner, Torben, Benboubker, Lotfi, Liu, Kevin, Hellemans, Peter, Masterson, Tara, Clemens, Pamela L, Luo, Man, Farnsworth, Andrew, Nahi, Hareth, Chari, Ajai

Volltext

Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Mult... von Clemens, Pamela L, Xu, Steven, Luo, Melody, Chari, Ajai, Usmani, Saad Z., Mateos, Maria-Victoria, van de Donk, Niels WCJ, Kaufman, Jonathan L, Moreau, Philippe, Oriol, Albert, Plesner, Torben, Benboubker, Lotfi, San-Miguel, Jesus F, Sun, X. Yu-Nien, Farnsworth, Andrew, Masterson, Tara, Hellemans, Peter, Qi, Ming, Nahi, Hareth

Volltext

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO) von Chari, Ajai, Mateos, Maria-Victoria, van de Donk, Niels WCJ, Kaufman, Jonathan L, Moreau, Philippe, Oriol, Albert, Plesner, Torben, Benboubker, Lotfi, Nahi, Hareth, Tang, Jie, Hellemans, Peter, Tromp, Brenda, Clemens, Pamela L, Farnsworth, Andrew, San-Miguel, Jesus F, Usmani, Saad Z.

Volltext

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study von Chari, Ajai, Nahi, Hareth, Mateos, Maria-Victoria, Lokhorst, Henk M., Kaufman, Jonathan L., Moreau, Philippe, Oriol, Albert, Plesner, Torben, Benboubker, Lotfi, Hellemans, Peter, Masterson, Tara, Clemens, Pamela L, Liu, Kevin, San-Miguel, Jesus F., Usmani, Saad Z

Volltext

Fetal fibronectin detection for prediction of preterm birth in low risk women von Hellemans, P., Gerris, J., Verdonk, P.

Volltext

Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study... von Chari, Ajai, Usmani, Saad Zafar, Mateos, Maria-Victoria, Van De Donk, Niels, Kaufman, Jonathan L., Moreau, Philippe, Rocafiguera, Albert Oriol, Plesner, Torben, Benboubker, Lotfi, Liu, Kevin, Hellemans, Peter, Masterson, Tara J., Clemens, Pamela L., Farnsworth, Andrew, Nahi, Hareth, San-Miguel, Jesus

Volltext

6MO Subcutaneous amivantamab administered every 4 weeks (Q4W) in patients with advanced solid malignancies: The phase Ib PALOMA study von Leighl, N., Minchom, A.R., Lee, K.H.H., Krebs, M.G., Cho, B.C., Kim, Y.J., Johnson, M.L., Sabari, J., Sanusi, B., Alhadab, A., Haddish-Berhane, N., Zemlickis, D., Mitselos, A., Collins, C., Baig, M., Bauml, J.M., Knoblauch, R.E., Hellemans, P., Sanborn, R.E.

Volltext

Evidence for genetic heterogeneity in inflammatory bowel disease (IBD); HLA genes in the predisposition to suffer from ulcerative colitis (UC) and Crohn's disease (CD) von BOUMA, G., OUDKERK POOL, M., CRUSIUS, J. B. A., SCHREUDER, G. M. TH, HELLEMANS, H. P. R., MEIJER, B. U. G. A., KOSTENSE, P. J., GIPHART, M. J., MEUWISSEN, S. G. M., PEÑA, A. S.

Volltext

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO) von Usmani, Saad Z, Nahi, Hareth, Mateos, Maria-Victoria, Lokhorst, Henk M., Chari, Ajai, Kaufman, Jonathan L., Moreau, Philippe, Oriol, Albert, Plesner, Torben, Benboubker, Lotfi, Hellemans, Peter, Masterson, Tara, Clemens, Pamela L, Ahmadi, Tahamtan, Liu, Kevin, San-Miguel, Jesús

Volltext

350 POSTER Measurement of mechanistic markers of histone deacetylase (HDAC) inhibition in samples from clinical trials von Hardcastle, A, Fong, P, Pickard, L, Arts, J, Janicot, M, Hellemans, P, DeBono, J, Aherne, W

Volltext

SUBCUTANEOUS DARATUMUMAB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE 1B STUDY (PAVO) von Mateos, MV, Chari, A, Nah, H, Lokhorst, H, Kaufman, JL, Moreau, P, Oriol, A, Plesner, T, Benboubker, L, Hellemans, P, Masterson, T, Clemens, PL, Liu, K, San-Miguel, J, Usmani, SZ

Volltext